Bibliographic information
GuidelineWHO recommendations on maternal and newborn care for a positive postnatal experience.
Year of Publication2022
Issuing InstitutionWHO
Recommendation
Maintained
In endemic communities with Schistosoma spp. prevalence of 10% or higher, WHO recommends annual preventive chemotherapy with praziquantel in a single dose for ≥ 75% up to 100% of pregnant women after the first trimester, and non-pregnant adolescent girls and women of reproductive age, including postpartum and/or lactating women, to control schistosomiasis morbidity and move towards eliminating the disease as a public health problem.
Context specific recommendation
Only in specific contexts
Certainty of evidence
Moderate
Notes and Remarks
Remarks
- These recommendations have been adapted and integrated from the 2022 WHO guideline on control and elimination of human schistosomiasis (84). Recommendation 16a for settings with prevalence above 10% was considered a strong recommendation based on moderate-certainty evidence. Recommendation 16b was considered a conditional recommendation based on low to very low-certainty evidence.
- The source guideline notes that, in endemic communities with Schistosoma spp. baseline prevalence of 10% or higher that demonstrate a lack of appropriate response to annual preventive chemotherapy despite adequate coverage (≥ 75%), WHO suggests biannual instead of annual preventive chemotherapy, in coordination with the interventions stated in Recommendation 3: Conditional recommendation (very lowcertainty evidence).
Also Featured In
This recommendation also appears in the following guidelines:
Originally Developed
Guideline
WHO guideline on control and elimination of human schistosomiasis.
Year2022
InstitutionWHO